Endothelial siRNA delivery in nonhuman primates using ionizable low-molecular weight polymeric nanoparticles

Area of Science:

• Biomedical research
• Gene therapy
• Nanotechnology

Background:

• Endothelial cell dysfunction is implicated in numerous diseases, including vascular disease, cancer, and diabetes.
• Current treatments often fail to address the root cause of endothelial dysfunction at the genetic level.

Purpose of the Study:

• To develop and evaluate an RNA-based therapy for correcting aberrant endothelial cell gene expression.
• To achieve efficient gene silencing in the endothelium of nonhuman primates using novel siRNA nanoparticles.

Main Methods:

• Systemic administration of small interfering RNA (siRNA) encapsulated in 7C1 nanoparticles via intravenous injection.
• Quantification of Tie2 mRNA levels in various organs (lung, heart, retina, kidney, pancreas, bone) post-treatment.
• Comprehensive safety assessments including blood chemistry, liver function tests, inflammatory cytokine analysis, and histological examination.

Main Results:

• A single intravenous dose of 7C1 nanoparticles delivering Tie2 siRNA reduced Tie2 mRNA by approximately 80% in lung endothelium.
• Significant Tie2 mRNA reduction was observed in multiple organs, including the heart, retina, kidney, pancreas, and bone.
• No significant adverse effects were detected in blood chemistry, liver function, inflammatory markers, or tissue histology, indicating a favorable safety profile.

Conclusions:

• This study presents the first successful demonstration of systemic endothelial gene silencing in multiple nonhuman primate organs using siRNA nanoparticles.
• The 7C1 nanoparticle delivery system shows potential for developing novel RNA-based therapies to treat human diseases associated with endothelial dysfunction.